Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings

James N. Ingle, Vera Jean Suman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The third-generation aromatase inhibitors anastrozole, exemestane and letrozole have become firmly established as the agents of choice in patients with tamoxifen-resistant tumors. Large, well-conducted, double-blind clinical trials directly comparing the non-steroidal aromatase inhibitors anastrozole and letrozole with tamoxifen in the advanced disease setting have matured. Based on these trials, there is sufficient evidence to choose one of these agents over tamoxifen because of a superior time to disease progression and acceptable toxicity which includes a lower incidence of thromboembolic complications. Information for the steroidal aromatase inhibitor exemestane will be forthcoming from a phase III trial which has completed accrual. Consistent with the findings in the advanced disease setting, a double-blind trial comparing letrozole with tamoxifen in the neoadjuvant setting revealed superiority for letrozole in terms of clinical response rate. This provides a strong impetus for further study of the aromatase inhibitors in the preoperative setting.

Original languageEnglish (US)
Pages (from-to)313-319
Number of pages7
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume86
Issue number3-5
DOIs
StatePublished - Sep 2003

Fingerprint

letrozole
Aromatase Inhibitors
exemestane
Tamoxifen
Breast Neoplasms
Toxicity
Disease Progression
Tumors
Clinical Trials
Incidence

Keywords

  • Anastrozole
  • Aromatase inhibitors
  • Clinical trials
  • Exemestane
  • Letrozole
  • Tamoxifen

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

@article{d16a030995ee4b52b3ae83c65ff6cb21,
title = "Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings",
abstract = "The third-generation aromatase inhibitors anastrozole, exemestane and letrozole have become firmly established as the agents of choice in patients with tamoxifen-resistant tumors. Large, well-conducted, double-blind clinical trials directly comparing the non-steroidal aromatase inhibitors anastrozole and letrozole with tamoxifen in the advanced disease setting have matured. Based on these trials, there is sufficient evidence to choose one of these agents over tamoxifen because of a superior time to disease progression and acceptable toxicity which includes a lower incidence of thromboembolic complications. Information for the steroidal aromatase inhibitor exemestane will be forthcoming from a phase III trial which has completed accrual. Consistent with the findings in the advanced disease setting, a double-blind trial comparing letrozole with tamoxifen in the neoadjuvant setting revealed superiority for letrozole in terms of clinical response rate. This provides a strong impetus for further study of the aromatase inhibitors in the preoperative setting.",
keywords = "Anastrozole, Aromatase inhibitors, Clinical trials, Exemestane, Letrozole, Tamoxifen",
author = "Ingle, {James N.} and Suman, {Vera Jean}",
year = "2003",
month = "9",
doi = "10.1016/S0960-0760(03)00373-X",
language = "English (US)",
volume = "86",
pages = "313--319",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "3-5",

}

TY - JOUR

T1 - Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings

AU - Ingle, James N.

AU - Suman, Vera Jean

PY - 2003/9

Y1 - 2003/9

N2 - The third-generation aromatase inhibitors anastrozole, exemestane and letrozole have become firmly established as the agents of choice in patients with tamoxifen-resistant tumors. Large, well-conducted, double-blind clinical trials directly comparing the non-steroidal aromatase inhibitors anastrozole and letrozole with tamoxifen in the advanced disease setting have matured. Based on these trials, there is sufficient evidence to choose one of these agents over tamoxifen because of a superior time to disease progression and acceptable toxicity which includes a lower incidence of thromboembolic complications. Information for the steroidal aromatase inhibitor exemestane will be forthcoming from a phase III trial which has completed accrual. Consistent with the findings in the advanced disease setting, a double-blind trial comparing letrozole with tamoxifen in the neoadjuvant setting revealed superiority for letrozole in terms of clinical response rate. This provides a strong impetus for further study of the aromatase inhibitors in the preoperative setting.

AB - The third-generation aromatase inhibitors anastrozole, exemestane and letrozole have become firmly established as the agents of choice in patients with tamoxifen-resistant tumors. Large, well-conducted, double-blind clinical trials directly comparing the non-steroidal aromatase inhibitors anastrozole and letrozole with tamoxifen in the advanced disease setting have matured. Based on these trials, there is sufficient evidence to choose one of these agents over tamoxifen because of a superior time to disease progression and acceptable toxicity which includes a lower incidence of thromboembolic complications. Information for the steroidal aromatase inhibitor exemestane will be forthcoming from a phase III trial which has completed accrual. Consistent with the findings in the advanced disease setting, a double-blind trial comparing letrozole with tamoxifen in the neoadjuvant setting revealed superiority for letrozole in terms of clinical response rate. This provides a strong impetus for further study of the aromatase inhibitors in the preoperative setting.

KW - Anastrozole

KW - Aromatase inhibitors

KW - Clinical trials

KW - Exemestane

KW - Letrozole

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0242541292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242541292&partnerID=8YFLogxK

U2 - 10.1016/S0960-0760(03)00373-X

DO - 10.1016/S0960-0760(03)00373-X

M3 - Article

C2 - 14623527

AN - SCOPUS:0242541292

VL - 86

SP - 313

EP - 319

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 3-5

ER -